Comparative Pharmacology
Head-to-head clinical analysis: BENZNIDAZOLE versus LAMPIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZNIDAZOLE versus LAMPIT.
BENZNIDAZOLE vs LAMPIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benznidazole is a nitroimidazole derivative that exerts trypanocidal activity against Trypanosoma cruzi. Its mechanism involves the reduction of the nitro group by a nitroreductase enzyme in the parasite, leading to the generation of toxic metabolites that damage parasite DNA and other cellular components.
Inhibits the enzyme G6PD (glucose-6-phosphate dehydrogenase) in Trypanosoma cruzi, leading to oxidative stress and parasite death.
5-7 mg/kg/day orally divided into two daily doses for 60 days. Maximum daily dose: 300 mg.
Nifurtimox (Lampit) for Chagas disease: adult dose 8-10 mg/kg/day orally in 3 divided doses for 90 days. For Chagas disease in children: 15-20 mg/kg/day orally in 3 divided doses for 90 days.
None Documented
None Documented
Clinical Note
moderateBenznidazole + Leflunomide
"The risk or severity of adverse effects can be increased when Benznidazole is combined with Leflunomide."
Clinical Note
moderateBenznidazole + Fingolimod
"Benznidazole may increase the immunosuppressive activities of Fingolimod."
Clinical Note
moderateBenznidazole + Tofacitinib
"Benznidazole may increase the immunosuppressive activities of Tofacitinib."
Clinical Note
moderatePimecrolimus + Benznidazole
Terminal elimination half-life is approximately 12 hours; may be prolonged in hepatic impairment.
Terminal elimination half-life is approximately 20 hours. In hepatic impairment, half-life may be prolonged by up to 2-fold.
Primarily renal excretion of metabolites; <5% unchanged drug. Approximately 20% in feces.
Renal excretion of unchanged drug accounts for 10% of the dose; biliary/fecal excretion accounts for approximately 90%, mainly as metabolites.
Category C
Category C
Antiprotozoal
Antiprotozoal
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benznidazole."